Dai Shiyi,Peng Suhua,Chen Siyuan,et al.Recent advances in researches and treatments of kaposiform hemangioendothelioma[J].Journal of Clinical Pediatric Surgery,2020,19(06):544-547,553.[doi:10.3969/j.issn.1671-6353.2020.06.016]
卡波西样血管内皮瘤的研究进展
- Title:
- Recent advances in researches and treatments of kaposiform hemangioendothelioma
- Keywords:
- Kaposiform Hemangioendothelioma; Therapy
- 分类号:
- R543;R732.2
- 摘要:
- 卡波西样血管内皮瘤（Kaposiform hemangioendothelioma，KHE）是一种好发于婴幼儿及儿童的、罕见的内皮源性、具有局部侵袭性的脉管肿瘤，表现为弥漫性血管与淋巴管的侵袭性增殖。KHE合并血小板减少、低纤维蛋白血症和凝血因子消耗，称为卡梅现象（Kasabach-Merritt phenomenon，KMP），可致严重并发症甚至死亡。目前，随着大家对KHE发病机制的认识，临床诊疗水平的不断提高，采用手术、动脉栓塞或长春新碱、西罗莫司等药物治疗可使得大多数患儿预后较好；但部分长期合并运动功能障碍与慢性疼痛的患儿，仍是治疗难点。为进一步提高临床医生对KHE的认识，本文拟对其临床特征、主要并发症及危险因素、发病机制和治疗等进行深入阐述，为临床治疗KHE提供经验。
- Abstract:
- As a rare,endotheliogenic and locally aggressive vascular neoplasm appearing predominantly in infants and toddlers,kaposiform hemangioendothelioma (KHE) is characterized by diffuse and invasive vascular and lymphatic proliferation.It may be associated with thrombocytopenia,hypofibrinemia and coagulation factor consumption,which is also known as Kasabach-Merritt phenomenon (KMP).KMP can cause serious complications and even death.With the continuous progress of pathogenesis,clinical diagnosis and treatments of surgery,embolization and using vincristine and sirolimus,most children have a decent prognosis.However,decreased range of motion and chronic pain are likely to be underappreciated in clinical practice.In this review,recent advances in researches and treatments of KHE were summarized.With a review of the relevant literature,the clinical characteristics,major complications and risk factors of KHE were extensively discussed for its optimal clinical managements.
参考文献/References:
1 Schmid I,Klenk AK,Sparber-Sauer MA,et al.Kaposiform hemangioendothelioma in children:a benign vascular tumor with multiple treatment options[J].World J Pediatr,2018,14(4):322-329.DOI:10.1007/s12519-018-0171-5.
2 Ji Y,Yang K,Peng S,et al.Kaposiform haemangioendothelioma:clinical features,complications and risk factors for Kasabach-Merritt phenomenon[J].Brit J Dermatol,2018,179(2):457-463.DOI:10.1111/bjd.16601.
3 Glaser K,Dickie P,Dickie BH.Proliferative cells from kaposiform lymphangiomatosis lesions resemble mesenchyme stem cell-like pericytes defective in vessel formation[J].J Pediatr Hematol Oncol,2018,40(8):e495-e504.DOI:10.1097/MPH.0000000000001284.
4 O’rafferty C,O’regan GM,Irvine AD,et al.Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon[J].Br J Haematol,2015,171(1):38-51.DOI:10.1111/bjh.13557.
5 Lim YH,Bacchiocchi A,Qiu J,et al.GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation[J].Am J Hum Genet,2016,99(2):443-450.DOI:10.1016/j.ajhg.2016.06.010.
6 Hall GW.Kasabach-Merritt syndrome:pathogenesis and management[J].Brit J Haematol,2001,112(4):851-862.DOI:10.1046/j.1365-2141.2001.02453.x.
7 Le Cras TD,Mobberley-Schuman PS,Broering M,et al.Angiopoietins as serum biomarkers for lymphatic anomalies[J].Angiogenesis,2017,20(1):163-173.DOI:10.1007/s10456-016-9537-2.
8 Croteau SE,Kozakewich HP,Perez-Atayde AR,et al.Kaposiform lymphangiomatosis:a distinct aggressive lymphatic anomaly[J].J Pediatr,2014,164(2):383-388.DOI:10.1016/j.jpeds.2013.10.013.
9 Ji Y,Chen SY,Yang KY,et al.Development of Kasabach-Merritt phenomenon following vaccination:more than a coincidence?[J].J Dermatol,2018,45(10):1203-1206.DOI:10.1111/1346-8138.14598.
10 Yue X,Zhao X,Dai YF,et al.Episode of Kasabach-Merritt phenomenon following Japanese encephalitis vaccination:case report[J].Vaccine,2017,35(48 Pt B):6594-6597.DOI:10.1016/j.vaccine.2017.08.011.
11 Choi JW,Na JI,Hong JS,et al.Intractable tufted angioma associated with Kasabach-Merritt syndrome[J].Ann Dermatol,2013,25(1):129-130.DOI:10.5021/ad.2013.25.1.129.
12 Liu QY,Jiang LL,Wu DT,et al.Clinicopathological features of Kaposiform hemangioendothelioma[J].Int J Clin Exp Pathol,2015,8(10):13711-13718.
13 Lisle JW,Bradeen HA,Kalof AN.Case report:kaposiform hemangioendothelioma in multiple spinal levels without skin changes[J].Clin Orthop Relat Res,2009,467(9):2464-2471.DOI:10.1007/s11999-009-0838-2.
14 Kim DW,Chung JH,Ahn SH,et al.Laryngeal kaposiform hemangioendothelioma:Case report and literature review[J].Auris Nasus Larynx,2010,37(2):258-262.DOI:10.1016/j.anl.2009.05.003.
15 Ji Y,Chen SY,Li LZ,et al.Kaposiform hemangioendothelioma without cutaneous involvement[J].J Cancer Res Clin Oncol,2018,144(12):2475-2484.DOI:10.1007/s00432-018-2759-5.
16 Ji Y,Chen SY,Xiang B,et al.Sirolimus for the treatment of progressive kaposiform hemangioendothelioma:A multicenter retrospective study[J].Int J Cancer,2017,141(4):848-855.DOI:10.1002/ijc.30775.
17 Mulliken JB,Young AE,Paletta FX.Vascular birthmarks[J].Plast Reconstr Surg,1990,85(3):471.DOI:10.1097/00006534-199003000-00027.
18 Gruman A,Liang MG,Mulliken JB,et al.Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon[J].J Am Acad Dermatol,2005,52(4):616-622.DOI:10.1016/j.jaad.2004.10.880.
19 Adams DM,Leonardo R,Brand?opeterman CM,et al.Vascular anomaly cases for the pediatric hematologist oncologists-An interdisciplinary review[J].Pediatr Blood Cancer,2017,65(3):e26716.DOI:10.1002/pbc.26716.
20 Oza VS,Mamlouk MD,Hess CP,et al.Role of sirolimus in advanced kaposiform hemangioendothelioma[J].Pediatr Dermatol,2016,33(2):e88-e92.DOI:10.1111/pde.12787.
21 Mahajan P,Margolin J,Iacobas I.Kasabach-Merritt phenomenon:classic presentation and management options[J].Clin Med Insights Blood Disord,2017,10:1179545X17699849.DOI:10.1177/1179545X17699849.
22 Triana PJ,Dore M,Vanesa CN,et al.Pancreatic kaposiform hemangioendothelioma not responding to sirolimus[J].Eur J Pediatr Surg,2017,5(1):e32-e35.DOI:10.1055/s-0037-1604358.
23 Liu XH,Li JY,Qu XH,et al.Clinical outcomes for systemic corticosteroids versus vincristine in treating kaposiform hemangioendothelioma and tufted angioma[J].Medicine (Baltimore),2016,95(20):e3431.DOI:10.1097/MD.0000000000003431.
24 Tlougan BE,Lee MT,Drolet BA,et al.Medical management of tumors associated with Kasabach-Merritt phenomenon:an expert survey[J].J Pediatr Hematol Oncol,2013,35(8):618-622.DOI:10.1097/MPH.0b013e318298ae9e.
25 Wu HW,Wang X,Zhang L,et al.Interferon-alpha therapy for refractory kaposiform hemangioendothelioma:a single-center experience[J].Sci Rep,2016,6(1):36261.DOI:10.1038/srep36261.
26 Liu XH,Li JY,Qu XH,et al.Treatment of kaposiform hemangioendothelioma and tufted angioma[J].Int J Cancer,2016,139(7):1658-1666.DOI:10.1002/ijc.30216.
27 Wang Z,Li K,Yao W,et al.Steroid-resistant kaposiform hemangioendothelioma:a retrospective study of 37 patients treated with vincristine and long-term follow-up[J].Pediatr Blood Cancer,2015,62(4):577-580.DOI:10.1002/pbc.25296.
28 Wiegand S,Wichmann G,Dietz A.Treatment of lymphatic malformations with the mTOR inhibitor sirolimus:a systematic review[J].Lymphat Res Biol,2018,16(4):330-339.DOI:10.1089/lrb.2017.0062.
29 Matsumoto H,Ozeki M,Hori T,et al.Successful everolimus treatment of kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon:clinical efficacy and adverse effects of mTOR inhibitor therapy[J].J Pediatr Hematol Oncol,2016,38(8):e322-e325.DOI:10.1097/MPH.0000000000000509.
30 Vierhuff W.Sirolimus in the treatment of vascular anomalies[J].Eur J Pediatr Surg,2017,27(1):86-90.DOI:10.1055/s-0036-1593383.
31 Russell TB,Rinker EK,Dillingham CS,et al.Pneumocystis JiroveciiPneumonia during sirolimus therapy for kaposiform hemangioendothelioma[J].Pediatrics,2018,141(Suppl 5):S421-S424.DOI:10.1542/peds.2017-1044.
32 Ying HR,Qiao C,Yang X,et al.A case report of 2 sirolimus-related deaths among infants with kaposiform hemangioendotheliomas[J].Pediatrics,2018,141(5):S425-S429.DOI:10.1542/peds.2016-2919.
相似文献/References:
[1]曹国庆 汤绍涛杨瑛李时望毛永忠王勇.腹腔镜治疗直肠乙状结肠型先天性巨结肠122例疗效分析[J].临床小儿外科杂志,2011,10(01):0.
CAO Guo qing,TANG Shao tao,YANG Ying et al..The clinical analysis of laparoscopic transanal puuthrough operation for rectosigmoild Hirschsprung disease (122 cases report).[J].Journal of Clinical Pediatric Surgery,2011,10(06):0.
[2]陆良生阮双岁毕允力陆毅群王翔葛琳娟肖现民.45例两性畸形患儿的诊断及治疗分析[J].临床小儿外科杂志,2011,10(01):0.
[3]刘鸿坚杨传民祁泳波王千于丹张晋绥张强李伟李友.经肛门改良Soave术治疗先天性巨结肠80例疗效分析[J].临床小儿外科杂志,2011,10(01):0.
[4]景登攀张根领孙蔓丽.改良Snodgrass术治疗尿道下裂疗效观察[J].临床小儿外科杂志,2011,10(01):0.
[5]许瑞江
洪锡伟
于向华
李文超.大年龄儿童发育性髋脱位术后再脱位的治疗[J].临床小儿外科杂志,2010,9(02):0.
XU Rui-jiang,HONG Xi-wei,YU Xiang-hua,et al.Surgical management for redislocation after open reduction of developmental dislocation of the hip in older children[J].Journal of Clinical Pediatric Surgery,2010,9(06):0.
[6]姜 海
汪 兵
吴永涛
苗武胜
吴 革.儿童肱骨远端骨骺分离的手术治疗[J].临床小儿外科杂志,2010,9(02):0.
Jiang hai,Wang bin,Wu yongtao,et al.The operative treatment in children’s distal humeral osteoepiphysis fracture.[J].Journal of Clinical Pediatric Surgery,2010,9(06):0.
[7]姜海吴永涛苗武胜梁晓军吴革汪兵张博皓.儿童移位型股骨颈骨折16例临床分析[J].临床小儿外科杂志,2010,9(03):0.
[8]王琪.儿童髂前上棘骨折27例疗效分析[J].临床小儿外科杂志,2010,9(03):0.
[9]王鹏高翟波罗淑颖.婴幼儿室间隔缺损合并肺动脉高压的外科治疗[J].临床小儿外科杂志,2010,9(03):0.
[10]张舰范学圣.小儿脾脏外伤保守治疗47例[J].临床小儿外科杂志,2010,9(03):0.
备注/Memo
收稿日期:2019-04-15。
基金项目:国家自然科学基金资助项目（编号：81401606/81400862）；四川大学优秀青年学者基金资助项目（编号：2015SU04A15）；四川省科技厅重点研发项目（编号：2019YFS0322）
通讯作者:吉毅,Email:jijiyuanyuan@163.com